Dengue Virus (DENV) infection can result in significant morbidity and mortality in the world. Treatment approach is believed to be supportive to regulate the provision of fluids and there is no specific therapy for DENV. (1-11) Corticosteroids are not recommended by the WHO in the management of dengue but empirically been used by clinicians based on immunological mechanisms in the pathogenesis of Dengue infection. (12) Evidence of the benefits and safety of corticosteroids for DENV infection is still limited in number and methodologies with varying results. (2, 5, 12-22)
Cytokine play an important role in the pathogenesis and severity DENV infection, especially TNF alpha, IL-1B, and IL-8. (23-28) Cytokines are associated with bleeding manifestations, activation of coagulation and fibrinolysis, (29-30) involved in the increased vascular permeability and disease morbidity. (31) Changes in cytokine levels have occurred in DENV infections changed significantly in mild and severe clinical conditions. (32-33)
Mononuclear phagocyte, such as dendritic cells and monocyte are a good cell to study dengue infection in vitro and in vivo. (34-37) Monocyte is DENV-infected leukocytes, although often in patients with DHF is often atypical lymphocytes and PMN obtained. (34) Monocytes from patients in the acute phase showed DENV-Ag during natural infection DF. (38)
TNF alfa and IL-1B produced by monocytes is an early cytokine that appears on DENV infection. (39-40) Macrophages in vitro will release TNF-α, IFN-α, IL-1β, IL-8, IL-12, MIP-1, and RANTES after infection but not IL-6, IL-15, or nitric oxide. (41) The study by Reis et al. (2007) showed that human monocytes from 15 healthy donors in the Brazilian monocyte infected with DENV can induce cytokines TNF-α, IFN-α, IL-6, and IL-10 which occur also in patients with DF. (42) Cytokine IL-1β, IL-8, IL-12, and IL-15 were not detected in cultured monocytes in which cytokines are produced at least in patients with DF. (31, 42) Interferon alpha has increased dramatically during defervescence DHF. (43)
Research at the cellular level swowed that the corticosteroids effects on cytokine production. Corticosteroids enter the cell that will bind to the receptors and will be interacting with buclear factor - kB (NF-kB) caused negative regulation of IL-8 and RANTES. Intitute of corticosteroids on the GRE in the nucleus of cells would inhibit the transcription of several cytokines including IL-1B, TNF alpha, GM-CSF, IL-2 to IL-6, IL-8, RANTES and MIP-1 alpha. (44) Kurane et al. (1993) measured the levels of IFN-α in the serum of patients with DHF and DF. The highest levels of IFN-α in patients with DHF and DF occured on the first day of devervescence phase and gradually decreases during deververcence. The research results indicate that IFN-α produced in high amounts in acute phase of DHF and DF. IFN-α level remained high in patients with DHF after phase of fever but not for the DF. (43)
Inhibitory effect of dexamethasone occurred on cytokine production by DENV infected monocytes and viral load reduction. (42) Dexamethasone working on the production of cytokines TNF-α, IFN-α and IL-10 by monocytes after infection with DENV-2. Dexamethasone effects on the production of TNF-α and translocation of NF-kβ, which is an important step for the induction of TNF-α by monocytes. (42)
Interleukin 1β, IL-6, and IL-10 is inhibited by dexamethasone after monocytes induced by lipopolysaccharide (LPS) bacteria in shock septik. (42) Dexamethasone does not alter significantly the production of IL-6 during DENV infection in vitro. Other cytokines related to severity DENV infection, such as IL-18 and TGF-β, (29) and dexamethasone effects need to be studied. (42)
Pathogenesis of dengue was believed due to the dysregulation of immune response. Monocytes / macrophages infected with DENV will secrete monokin that play a role in the manifestations of DHF / DSS. During the acute phase, mononuclear cells proliferate poorly in response to mitogen and dengue antigens as detected by the radiolabel of timidine. During the convalescent phase, limfoploriferatif response returned to normal. (29)
Dexamethasone, inhibits expression of inflammatory mediators such as cytokines proinflamatory. (45) Corticosteroids inhibit monocyte function including the release of TNF alpha stimulated by endotoxin. Monocytes also release TNF receptor (cTNF-R) that modulates the bioactivity of TNF-α. Effect increased with increasing concentration of dexamethasone. Dexamethasone concentraton of 1 umol/L can inhibit the released of sTNF-RT75 by monocyte as much as 86% and 40% in culture. Dexamethasone also reduced TNF bioactivity in peripheral monocyte cultures, especially TNF-α. Dexamethasone also inhibits the release of IL-1β and IL-1ra by monocytes culture. (45)
Dexamethasone, inhibits expression of inflammatory mediators such as cytokines proinflamatory. (45) Corticosteroids inhibit monocyte function including the release of TNF alpha stimulated by endotoxin. Monocytes also release TNF receptor (cTNF-R) that modulates the bioactivity of TNF-α. Effect increased with increasing concentration of dexamethasone. Dexamethasone concentraton of 1 umol/L can inhibit the released of sTNF-RT75 by monocyte as much as 86% and 40% in culture. Dexamethasone also reduced TNF bioactivity in peripheral monocyte cultures, especially TNF-α. Dexamethasone also inhibits the release of IL-1β and IL-1ra by monocytes culture. (45)
The study by Reis et al (2007) have tested the effect of dexamethasone on cytokine production by monocytes infected by DENV in vitro. (42) TNF-α, IL-6, IL-10, and IFN-α was measured in cell supernatant PBML 10-15 different donors with immunoassay. Inhibition occurred significantly in monocyte cultures were added dexamethasone especially TNF-α, and IL-10. Interleukin 6 is not statistically different although 8 of the 15 donors PBML showed resistance> 35% (Figure 1). (42)
Downregulation of IFN-α initiate immunomodulatory effects of dexamethasone. This effect is not related to different viral clearance with antiviral effects caused by other molecules such as nitric oxide, which is known for controlling DENV replication in monocytes. Interleukin 10 38 46 block in STAT-1 and IRF-1, activation factor for nosocomial infection, whose expression can lead to inhibition of nitric oxide effect on DENV replication. (47, 48) After the downregulation of IL-10 by dexamethasone, activation of nosocomial infection can occur, resulting in a more efficient nitric oxide to the antiviral effects on monocytes. (42)
Dexamethasone acts as immunomodulator DENV infection that can reduce viral load and reduces the inflammatory reaction caused by a virus. (49) Dexamethasone significantly inhibited expression of DENV antigens and reduce the number of infected cells in 11 of the 15 culture monocytes. DENV particles decreased significantly after administration of dexamethasone for 2 days (Figure 1). (42) Although dexamethasone has a very interesting effect on in vitro models of dengue infection, clinical evidence is insufficient to recommend the use of corticosteroids in managing DHF / DSS.
1. Anonim. Infeksi virus dengue. In: Soedarmo SSP, Garna H, Hadinegoro SRS, Satari HI, editors. Buku ajar infeksi & pediatri tropis. 2 ed. Jakarta: Badan Penerbit IDAI, 2010:155-81.
2. Azis AL, Kushartono H, Darmawati I. Tatalaksanan sindroma renjatan dengue. Applied management of dengue viral infection in children. Kediri: IDAI Jatim Komisariat Jatim IV, 2010:99-113.
3. Basuki PS. Diagnosis infeksi virus dengue: penuntun bagi petugas kesehatan di daerah. Applied management of dengue viral infection in children. Kediri: IDAI Jatim komisariat Jatim IV, 2010:63-81(fulltex).
4. Basuki PS. Dengue 2010: apa yang baru? Workshop & simposium tatalaksana muthakir kasus demam pada anak: IDAI Jatim Kosisariat Jember, 2010:80-109.
5. Husada D. Pearls dan pitfalls, gosip, fakta, serta kontroversi seputar infeksi virus dengue. Applied management of dengue viral infection in children. Kediri: IDAI cabang Jatim Komisariat Jatim IV, 2010:125-46.
6. Ismudijanto. Epidemiologi infeksi virus dengue: broader coverage, older patient and higher mortality. Applied management of dengue viral infection in children. Kediri: IDAI Jatim komisariat Jatim IV, 2010:1-9.
7. Soemakto, Yuliarto S, Rridewi I. Mengenal tanda awal dan tanda bahaya infeksi dengue. Aplied Management of dengue viral infection in children. Kediri: IDAI Jatim komisariat Jatim IV, 2010:47-61.
8. WHO. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. 2 ed. Geneva: World Health Organization, 1997.
9. WHO. Guidelines for treatments of dengue fever/dengue hemorrhagic fever in small hospital. New Delhi: World Health Organization, 1999.
10. WHO. Dengue, dengue hemorrhagic fever and dengue shock sundrome in the context of integrated management of childhood ilness. Geneva: World Health Organization, 2005.
11. WHO. Clinical management and delivery clinical service. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization, 2009.
12. Rajapakse S, Ranasinghe C, Rodrigo C. Corticosteroid therapy in dengue infection- opinions of junior doctors. J Glob Infect Dis 2010;2(2):199-200.
13. Futrakul P, Poshyachinda M, Mitrakul C, Kwakpetoon S, Unchumchoke P, Teranaparin C, et al. Hemodynamic response to high-dose methyl prednisolone and mannitol in severe dengue-shock patients unresponsive to fluid replacement. Southeast Asian J Trop Med Public Health 1987;18(3):373-9.
14. Futrakul P, Vasanauthana S, Poshyachinda M, Mitrakul C, Cherdboonchart V, Kanthirat V. Pulse therapy in severe form of dengue shock syndrome. J Med Assoc Thai 1981;64(10):485-91.
15. Min M, U T, Aye M, Shwe TN, Swe T. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health 1975;6(4):573-9.
16. Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006;3:CD003488(fulltext).
17. Pongpanich B, Bhanchet P, Phanichyakarn P, Valyasevi A. Studies on dengue hemorrhagic fever. Clinical study: an evaluation of steroids as a treatment. J Med Assoc Thai 1973;56(1):6-14.
18. Rajapakse S. Corticosteroids in the treatment of dengue illness. Trans R Soc Trop Med Hyg 2009;103(2):122-6.
19. Sumarmo. The role of steroids in dengue shock syndrome. Southeast Asian J Trop Med Public Health 1987;18(3):383-9.
20. Sumarmo, Talogo W, Asrin A, Isnuhandojo B, Sahudi A. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 1982;69(1):45-9.
21. Sumarmo, Widya MS, Martoatmodjo K. Cliical observations on dengue shoch syndrome (an evaluation of steroid treatment). Pediatr Indones 1975;15:151-60.
22. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 1993;92(1):111-5.
23. Vitarana T, de Silva H, Withana N, Gunasekera C. Elevated tumour necrosis factor in dengue fever and dengue haemorrhagic fever. Ceylon Med J 1991;36(2):63-5.
24. Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 1993;48(3):324-31.
25. Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, Buurman WA, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998;177(3):778-82.
26. Raghupathy R, Chaturvedi UC, Al-Sayer H, Elbishbishi EA, Agarwal R, Nagar R, et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 1998;56(3):280-5.
27. Braga EL, Moura P, Pinto LM, Ignacio SR, Oliveira MJ, Cordeiro MT, et al. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem Inst Oswaldo Cruz 2001;96(2):229-32.
28. Fink J, Gu F, Vasudevan SG. Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev Med Virol 2006;16(4):263-75.
29. Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, et al. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 2001;204(4):494-507.
30. Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, et al. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 2002;87(1):42-6.
31. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006;19(5):429-36.
32. Avila-Aguero ML, Avila-Aguero CR, Um SL, Soriano-Fallas A, Canas-Coto A, Yan SB. Systemic host inflammatory and coagulation response in the Dengue virus primo-infection. Cytokine 2004;27(6):173-9.
33. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 2004;189(2):221-32.
34. Scott RM, Nisalak A, Cheamudon U, Seridhoranakul S, Nimmannitya S. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J Infect Dis 1980;141(1):1-6.
35. Hotta H, Wiharta AS, Hotta S, Homma M. Dengue type 2 virus infection in human peripheral blood monocyte cultures. Microbiol Immunol 1984;28(10):1099-109.
36. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239(4839):476-81.
37. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000;6(7):816-20.
38. Neves-Souza PC, Azeredo EL, Zagne SM, Valls-de-Souza R, Reis SR, Cerqueira DI, et al. Inducible nitric oxide synthase (iNOS) expression in monocytes during acute Dengue Fever in patients and during in vitro infection. BMC Infect Dis 2005;5:64.
39. Espina LM, Valero NJ, Hernandez JM, Mosquera JA. Increased apoptosis and expression of tumor necrosis factor-alpha caused by infection of cultured human monocytes with dengue virus. Am J Trop Med Hyg 2003;68(1):48-53.
40. Bosch I, Xhaja K, Estevez L, Raines G, Melichar H, Warke RV, et al. Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J Virol 2002;76(11):5588-97.
41. Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 2002;76(19):9877-87.
42. Reis SR, Sampaio AL, Henriques MG, Gandini M, Azeredo EL, Kubelka CF. An in vitro model for dengue virus infection that exhibits human monocyte infection, multiple cytokine production and dexamethasone immunomodulation. Mem Inst Oswaldo Cruz 2007;102(8):983-90.
43. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg 1993;48(2):222-9.
44. Harsono A, Endaryanto A. Penggunaan kortikosteroid di bidang alergi pada anak. In: Soegijanto S, Poerwodibroto S, Kaspan MF, Sarwono E, Soejoso DA, Noer MS, et al., editors. Continuing education ilmu kesehatan anak, krtikosteroid pada anak. Surabaya: Laboratorium/SMF Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Airlangga, 1998:71-90.
45. Joyce DA, Kloda A, Steer JH. Dexamethasone suppresses release of soluble TNF receptors by human monocytes concurrently with TNF-alpha suppression. Immunol Cell Biol 1997;75(4):345-50.
46. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007;88(Pt 2):365-75.
47. Mahalingam S, Lidbury BA. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc Natl Acad Sci U S A 2002;99(21):13819-24.
48. Dell'Albani P, Santangelo R, Torrisi L, Nicoletti VG, de Vellis J, Giuffrida Stella AM. JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. J Neurosci Res 2001;65(5):417-24.
49. Moreno L, Jacoby DB, Fryer AD. Dexamethasone prevents virus-induced hyperresponsiveness via multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 2003;285(2):L451-5.
We tried to get pregnant for a few years in a local clinic. There were no results. We've tried everything possible but nothing. We were recommended to use donor eggs. I knew we have to try herbal made medicine. I was terrified. I didn't know how to go about it and where to begin my search. When my friend recommended me to Dr Itua herbal medicine in Western African. I thought she was joking. I knew nothing about that country and I was afraid with shame I must say I thought it was a little bit...wild? Anyway she convinced me to at least check it out. I've done the research and thought that maybe this really is a good idea. Dr Itua has reasonable prices. Also it has high rates of successful treatments. Plus it uses Natural Herbs. Well I should say I was convinced. My Husband gave it a try and now we can say it was the best decision in our lives. We were trying for so long to have a child and suddenly it all looked so simple. The doctors and staff were so confident and hopeful they projected those feelings on me too. I am so happy to be a mother and eternally thankful to Dr Itua and Lori My Dear Friend. Don’t be afraid and just do it! Try Dr itua herbal medicine today and sees different in every situation.Dr Itua Contact Info...Whatsapp+2348149277967/drituaherbalcenter@gmail.com Dr Itua have cure for the following diseases.All types of cancer,Liver/Kidney inflammatory,Fibroid,Infertility.Diabetes,Herpes Virus,Diabetis,Bladder cancer,Brain cancer,Esophageal cancer,Gallbladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma. Intestinal cancer,Kidney cancer,Leukemia,Liver cancer,Lung cancer,Melanoma,Mesothelioma,Multiple myeloma,Neuroendocrine tumors. Non-Hodgkin lymphoma,Oral cancer,Ovarian cancer,Sinus cancer,Skin cancer,Soft tissue sarcoma,Spinal cancer,Stomach cancer. Testicular cancer,Throat cancer,Thyroid Cancer,Uterine cancer,Vaginal cancer,Vulvar cancerBipolar Disorder, Bladder Cancer,Colorectal Cancer,HPV,Breast Cancer,Anal cancer.Appendix cancer.,Kidney Cancer,Prostate Cancer,Glaucoma., Cataracts,Macular degeneration,Adrenal cancer.Bile duct cancer,Bone cancer.Cardiovascular disease,Lung disease.Enlarged prostate,OsteoporosisAlzheimer's disease,Brain cancer.Dementia.Weak Erection,Love Spell,Leukemia,Fribroid,Infertility,Parkinson's disease,Inflammatory bowel disease ,Fibromyalgia.
BalasHapus